Unraveling the NLRP family: Structure, function, activation, critical influence on tumor progression, and potential

Xueqing Zhou1, Yongguang Tao1, Ying Shi1

  • 1Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, 410013, China.

Cancer Letters
|October 4, 2024
PubMed

Insights

Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing proteins (NLRPs) are crucial for innate immunity and cancer progression. Targeting NLRPs offers a promising therapeutic strategy, potentially enhancing immune checkpoint inhibitor efficacy.

Area of Science:

  • Immunology
  • Oncology

Background:

  • The innate immune system relies on pattern recognition receptors (PRRs) for initial defense.
  • Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing proteins (NLRPs) are key PRRs that form inflammasomes, regulating inflammation and innate immunity.

Purpose of the Study:

  • To provide a comprehensive overview of NLRP structure, function, and activation mechanisms.
  • To explore the role of NLRPs in cancer progression and their potential as therapeutic targets.

Main Methods:

  • Literature review focusing on NLRPs' role in immunity and cancer.
  • Analysis of NLRPs' differential expression and impact on cancer hallmarks.
  • Examination of NLRPs as therapeutic targets, including combination strategies with immune checkpoint inhibitors.

Main Results:

  • NLRPs are significantly implicated in various human cancers.
  • NLRPs influence cancer progression by modulating immune responses, cell fate, and proliferation.
  • NLRPs represent promising therapeutic targets in oncology.

Conclusions:

  • NLRPs play a critical role in both innate immunity and cancer development.
  • Targeting NLRPs may offer novel therapeutic avenues for cancer treatment.
  • Combining NLRP-targeted therapies with immune checkpoint inhibitors shows potential clinical value.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K